Acacia Research Corporation — 2015 Form 10-K
Business and reporting period. The filing reports the fiscal year ended December 31, 2015; quarterly data include the fourth quarter. Acacia’s operating subsidiaries acquire or control patent rights, then license and enforce them, sharing recoveries with patent owners and bearing associated legal and investment costs. The company reported more than 1,490 license agreements across 185 programs to date.
Financial performance and liquidity
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | $125.0 million | $130.9 million |
| Operating loss | $152.6 million | $62.2 million |
| Net loss attributable to Acacia | $160.0 million | $66.0 million |
| Diluted loss per share | $3.25 | $1.37 |
| Cash from operating activities | $(9.9) million | $4.2 million |
| Cash, cash equivalents, restricted cash and short-term investments | $145.9 million | $193.0 million |
| Working capital | $150.7 million | $172.8 million |
2015 revenue declined 4%; 63 new revenue agreements were executed versus 88 in 2014, while average revenue per agreement increased to $1.985 million from $1.487 million. Three licensees represented 24%, 20% and 16% of 2015 revenue. Gross or operating margin is not separately presented as a headline metric; the company recorded substantial patent amortization and litigation costs. 2015’s loss included $74.7 million of patent impairment and $30.1 million of goodwill impairment, both noncash. Total assets were $347.9 million and total liabilities $33.7 million at year-end. The filing reports no long-term debt or committed credit lines.
Fourth-quarter 2015 revenue was $37.5 million and net loss attributable to Acacia was $115.9 million, including $74.7 million of patent impairment and $30.1 million of goodwill impairment. Fourth-quarter 2014 revenue was $31.0 million and net loss was $16.2 million.
Material changes, outlook and risks
- Patent portfolio impairment charges rose from $3.5 million in 2014 to $74.7 million in 2015. Management cited adverse litigation outcomes, reduced expected cash flows, and decisions to discontinue investment in certain portfolios. Goodwill was fully impaired following adverse legal developments and a sustained decline in the company’s share price.
- The Adaptix subsidiary received a jury verdict in December 2015 finding asserted patent claims invalid and not infringed. Adaptix filed post-trial motions and was evaluating an appeal. Acacia said it had more than five patent infringement cases scheduled for trial within the following six months; dates and outcomes could change.
- Management stated that cash, investments and anticipated operating cash flows were expected to meet requirements through at least March 2017. This is not revenue or earnings guidance; the filing provides no specific financial forecast. Cash from operations was negative in 2015, and future licensing receipts are inherently uneven and difficult to predict.
- Patent-related litigation and licensing expenses were $39.4 million, up 5%. Management expected these expenses to fluctuate and anticipated costs related to upcoming trials, international enforcement and portfolio prosecution.
- Patent intake fell to three new portfolios in 2015, versus six in 2014 and 25 in 2013. Management attributed the decline partly to a strategic shift toward fewer, higher-quality portfolios and to increased enforcement complexity and reduced availability of suitable assets.
- On February 23, 2016, the board ended the $0.50 annual dividend policy, citing financial performance, available cash, cash needs and alternative uses of capital. Acacia said it did not anticipate cash dividends in the foreseeable future.
- Other notable exposures include concentration in a small number of licensees and receivables; potential adverse litigation rulings, appeals, fee awards or sanctions; patent invalidation or narrowed claims; and changing patent laws and procedures. A $10.7 million cash deposit secures a German-court injunction guarantee, potentially payable if the ruling is successfully appealed or amended. The guarantee automatically extends unless extinguished under applicable law.
Investor verification priorities
- Review the assumptions and portfolio-level detail supporting the $74.7 million patent and $30.1 million goodwill impairment charges, and the impact of the Adaptix verdict and other adverse cases.
- Assess whether the concentrated licensee base can sustain collections: three licensees generated 60% of 2015 revenue, and two represented 93% of year-end receivables.
- Track cash conversion, receivable collections and the $10.7 million restricted-cash guarantee against management’s liquidity outlook; verify whether the German guarantee was extended or extinguished.
- Evaluate the pipeline and timing of licensing programs and scheduled trials, given lower portfolio intake, variable revenue and expected litigation spending.
- Confirm the effect of the dividend termination on capital allocation and shareholder returns. The filing reports effective disclosure controls and internal control over financial reporting, with unqualified auditor opinions.